Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL

Video

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope in Duarte, CA, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Patients who have relapsed/refractory CLL or SLL and fail ibrutinib (Imbruvica) or venetoclax (Venclexta) have an unmet need for appropriate therapy, says Siddiqi.

The TRANSCEND CLL 004 trial, an open-label, multicenter study, enrolled patients who had received ≥2 lines of therapy, including BTK inhibitors, to receive the investigational CAR T-cell product, lisocabtagene maraleucel (JCAR017). The best overall response rate in 15 evaluable patients was 87%, with 7 patients (47%) achieving complete response.

Eradication of minimal residual disease in the blood was also seen in 67% of patients by day 30, making this an excellent option for this patient population, Siddiqi concludes.

<<< 15th International Conference on Malignant Lymphoma

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.